Skip to main content
Premium Trial:

Request an Annual Quote

Nastech Wins Phase I SBIR Grant to Develop siRNA-Based Flu Drugs

NEW YORK (GenomeWeb News) – Nastech Pharmaceutical has obtained a Phase I Small Business Innovation Research grant from the National Institutes of Health to help it develop small-interfering RNA influenza drugs.
 
The company did not disclose the mount of the grant but Phase I SBIRs typically do not exceed $100,000.
 
Nastech is developing siRNA therapeutics that specifically target conserved regions of the influenza viral genome. The company obtained the methods to do this when it acquired Galenea in February 2006.
 
The grant will help Nastech to design and optimize siRNAs against seasonal and avian influenza viruses, test in vivo activity of new siRNA delivery agents, and evaluate viral drug resistance mechanisms, Nastech said in a statement.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.